The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for revolutionary treatments and substantial returns is certain, the associated risks are also significant. Man